Tellgen

Tellgen FCF Growth

The Year-over-Year Free Cash Flow Growth of Tellgen (300642.SZ) as of Nov 19, 2026 is -2.86 %. In the previous year, Year-over-Year Free Cash Flow Growth was 210.75 % — a change of -101.36% (lower).

FCF Growth

-2.86 %

YoY

-101.36%

Last updated:

Year-over-Year Free Cash Flow Growth of Tellgen is 2025 -2.86 % . Year-over-Year Free Cash Flow Growth of Tellgen was 2024 210.75 % . It decreases by -101.36% lower compared to the previous year.

The Tellgen FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
-45.02 CNY
Jan 1, 2019
343.98 CNY
Jan 1, 2020
-76.75 CNY
Jan 1, 2021
-279.47 CNY
Jan 1, 2022
414.01 CNY
Jan 1, 2023
-74.30 CNY
Jan 1, 2024
210.75 CNY
Jan 1, 2025
-2.86 CNY
The Tellgen FCF Growth history
YEARFCF GrowthYoY
-2.86 %-101.36%
210.75 %-383.66%
-74.30 %-117.95%
414.01 %-248.14%
-279.47 %+264.14%
-76.75 %-122.31%
343.98 %-864.08%
-45.02 %+417.05%
-8.71 %-132.18%
27.06 %-34.31%
41.19 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tellgen Stock analysis

What does Tellgen do? Tellgen Corp develops, manufactures, and markets molecular diagnostic products including immunodiagnostic, molecular diagnostic, and biochemical diagnostic products. Their portfolio features tumor marker detection, HPV nucleic acid testing, autoimmune disease detection, and lung cancer methylation mutation detection products. The company targets healthcare providers and laboratories seeking advanced diagnostic solutions for disease detection and monitoring. Tellgen Corp generates revenue through the sale of these specialized diagnostic products to medical institutions and healthcare facilities. The firm's product lines focus on specific diagnostic needs such as cancer screening and infectious disease testing. Immunodiagnostic products detect antibodies and antigens, molecular diagnostic products analyze genetic material, and biochemical diagnostic products measure metabolic markers. Tellgen Corp sells these products directly to hospitals, clinics, and diagnostic laboratories across China and potentially internationally. Tellgen Corp's revenue streams come from the commercialization of its diagnostic product portfolio. The company's offerings address key healthcare challenges including early cancer detection and infectious disease management. Their products are designed to support clinical decision-making and patient care pathways in medical settings. Tellgen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tellgen stock

Year-over-Year Free Cash Flow Growth of Tellgen is -2.86 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Tellgen since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Tellgen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Tellgen

All Key Metrics — Tellgen